<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00665067</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 07-0548-00107</org_study_id>
    <secondary_id>P01CA108671-05</secondary_id>
    <secondary_id>MPD-RC 107</secondary_id>
    <nct_id>NCT00665067</nct_id>
  </id_info>
  <brief_title>Correlative Biomarker Study in Patients With Myeloproliferative Disorders</brief_title>
  <official_title>Correlative Biomarker Study for MPD-RC Treatment Studies in the Philadelphia Chromosome Negative MPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Myeloproliferative Disorders-Research Consortium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Researchers will use abnormal blood and/or bone marrow cells, or materials derived from these
      abnormal cells, like DNA, RNA, protein or plasma, in laboratory studies. Toenail clippings
      will provide normal material like DNA for comparison with the abnormal material derived from
      the blood and/or bone marrow. The results of these studies will be correlated with subjects'
      disease symptoms and response to their experimental treatment. The MPD-RC researchers are
      interested in studying molecules from the blood and bone marrow, the exact molecules changing
      over time with the investigators choosing only the most promising for investigation.

      The investigators are attempting to better understand the causes of MPD and to develop
      improved methods for the diagnosis and treatment of these diseases. These syndromes carry a
      high risk of developing leukemia. It is important to continue to learn more about these blood
      cancers and to learn more about the effectiveness and potential side effects of various
      treatments. It is believed that further basic knowledge about these cancer cells as well as
      the effects of treatment will lead to the improvement of current therapies and the
      development of entirely new treatments for these diseases. The MPD-RC is hoping to determine
      if a number of laboratory tests (biomarkers) will allow for the prediction of response in
      future patients to the treatment they would receive.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To collect and store tissue samples from patients with myeloproliferative disorders (PV,IM,and ET). Tissue samples will be used to perform a variety of biomarker studies to monitor the effects of a particular therapeutic intervention.</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">860</enrollment>
  <condition>Myeloproliferative Disease</condition>
  <condition>Myelofibrosis</condition>
  <condition>Idiopathic Myelofibrosis</condition>
  <condition>Essential Thrombocythemia</condition>
  <condition>Polycythemia Vera</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Leftover tissue will be asked for to be stored in the MPD-RC Tissue Bank
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects enrolled in MPD-RC treatment protocols.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients are to be registered to this study if they meet the eligibility criteria for
             one of the MPD-RC treatment protocols linked to this study.

          -  Patients diagnosed with the following Myeloproliferative disorders including:
             polycythemia vera (PV), idiopathic myelofibrosis (IM), and essential thrombocythemia
             (ET) who are participating in treatment protocols of the MPD-RC are eligible.

          -  Patients must have signed an informed consent to participate in a Myeloproliferative
             Disorders Research Consortium (MPD-RC) treatment study to which this protocol is a
             companion study. The subject must also have signed a consent to participate in this
             mandatory companion study.

        Exclusion Criteria:

        See inclusion criteria.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rona S Weinberg, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Myeloproliferative Disorders-Research Consortium</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Mascarenhas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rona S Weinberg, PhD</last_name>
    <phone>(212) 570-3412</phone>
    <email>rweinberg@nybloodcenter.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ronald Hoffman, MD</last_name>
    <phone>(212) 241-2297</phone>
    <email>ronald.hoffman@mssm.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruben Mesa, MD</last_name>
      <phone>480-301-8335</phone>
      <email>mesa.ruben@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Ruben Mesa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Palo Alto Clinic</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Liebowitz, MD</last_name>
      <phone>650-853-2905</phone>
      <email>leibowd@pamf.org</email>
    </contact>
    <investigator>
      <last_name>David Liebowitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgetown University</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <zip>20057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Craig Kessler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elliot Winton, MD</last_name>
      <phone>404-778-5871</phone>
      <email>ewinton@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Elliot Winton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Damiano Rondelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Baer, MD</last_name>
      <phone>410-328-8708</phone>
      <email>mbaer@umm.edu</email>
    </contact>
    <investigator>
      <last_name>Maria Baer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Mascarenhas, MD</last_name>
      <phone>212-241-3417</phone>
      <email>john.mascarenhas@mssm.edu</email>
    </contact>
    <investigator>
      <last_name>John Mascarenhas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tsiporah Shore, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Blood Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>60065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rona S Weinberg, PhD</last_name>
      <phone>212-570-3412</phone>
      <email>rweinberg@nybloodcenter.org</email>
    </contact>
    <investigator>
      <last_name>Rona S Weinberg, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Murat Arcasoy, MD</last_name>
      <phone>919-668-6309</phone>
      <email>arcas001@mc.duke.edu</email>
    </contact>
    <investigator>
      <last_name>Murat Arcasoy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Baptist Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dmitry Berenzon, MD</last_name>
      <phone>336-716-5847</phone>
      <email>dberenzo@wfubmc.edu</email>
    </contact>
    <investigator>
      <last_name>Dmitry Berenzon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Klisovic, MD</last_name>
      <phone>614-293-4696</phone>
      <email>rebecca.klisovic@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Rebecca Klisovic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Geisinger Cancer Center</name>
      <address>
        <city>Hazleton</city>
        <state>Pennsylvania</state>
        <zip>18201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harsh Gandhi, MD</last_name>
      <phone>570-459-2901</phone>
      <email>hgandhi1@geisinger.edu</email>
    </contact>
    <investigator>
      <last_name>Harsh Gandhi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Hexner, MD</last_name>
      <phone>215-662-4137</phone>
      <email>elizabeth.hexner@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Elizabeth Hexner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Josef Prachal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vikas Gupta, MD</last_name>
      <phone>416-946-6546</phone>
      <email>Vikas.Gupta@uhn.on.ca</email>
    </contact>
    <investigator>
      <last_name>Vikas Gupta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti di Bergamo</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alessandro Rambaldi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florence</name>
      <address>
        <city>Florence</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Allessandro Vannucchi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Martino Genova</name>
      <address>
        <city>Genova</city>
        <zip>11632</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Bacigalupo, MD</last_name>
      <phone>39 010-555469</phone>
      <email>andrea.bacigalupo@hsamartino.it</email>
    </contact>
    <investigator>
      <last_name>Andrea Bacigalupo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Matteo Hospital</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gianni Barosi, MD</last_name>
      <phone>39-038-2503636</phone>
      <email>barosig@smateo.py.it</email>
    </contact>
    <investigator>
      <last_name>Gianni Barosi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mario Cazzola, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universita Cattolica del Sacro Cuore</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Leone, MD</last_name>
      <phone>39-063-0154180</phone>
      <email>gleone@rm.unicatt.it</email>
    </contact>
    <investigator>
      <last_name>Giuseppe Leone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas' NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire Harrison, MD</last_name>
      <phone>02 71882739</phone>
      <email>claire.harrison@gstt.sthames.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Claire Harrison, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Italy</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Sweden</country>
  </removed_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2008</study_first_submitted>
  <study_first_submitted_qc>April 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2008</study_first_posted>
  <last_update_submitted>October 4, 2017</last_update_submitted>
  <last_update_submitted_qc>October 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myeloproliferative Disease</keyword>
  <keyword>Myelofibrosis</keyword>
  <keyword>Idiopathic Myelofibrosis</keyword>
  <keyword>Essential Thrombocythemia</keyword>
  <keyword>Polycythemia Vera</keyword>
  <keyword>Biomarkers</keyword>
  <keyword>Philadelphia Chromosome Negative</keyword>
  <keyword>Clonal Hematopoietic malignancies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Polycythemia</mesh_term>
    <mesh_term>Polycythemia Vera</mesh_term>
    <mesh_term>Thrombocytosis</mesh_term>
    <mesh_term>Thrombocythemia, Essential</mesh_term>
    <mesh_term>Philadelphia Chromosome</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

